Cantor Fitzgerald upped their price target on shares of NewLink Genetics Corp. (NASDAQ:NLNK) from $30.00 to $34.00 in a research note issued on Wednesday, American Banking News reports. Cantor Fitzgerald’s price objective suggests a potential upside of 5.52% from the stock’s previous close. NewLink Genetics Corp (NASDAQ:NLNK) shares after opening at $30.82 moved to $31.33 on last trade day and at the end of the day closed at $27.96. Company price to sales ratio in past twelve months was calculated as 658.25 and price to cash ratio as 11.77. NewLink Genetics Corp (NASDAQ:NLNK) showed a positive weekly performance of -10.07%.
After a day of good news, Northwest Biotherapeutics, Inc (NASDAQ:NWBO) faced some challenges on Wednesday, pushing its stocks lower by 12%. Firstly, the company has been downgraded by the research firm Oppenheimer from outperform to perform, in light of concerns over its valuations. The firm believes that the recent bull run reflects the fair value of the company’s assets including its DCVax pipeline. Secondly, the company also took in some brunt from the allegations of Adam Feuerstein, who penned in his report that the company deliberately delayed its Hospital Exemption approval news and raised questions about the company’s trial claims. However, during the later part of the day, Northwest Biotherapeutics, Inc (NASDAQ:NWBO) rubbished the allegations through releasing an official statement. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) shares advanced 3.37% in last trading session and ended the day on $7.98. NWBO return on equity ratio is recorded as 603.80% . Northwest Biotherapeutics, Inc (NASDAQ:NWBO) yearly performance is 121.67%.
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) and Bristol-Myers Squibb Company (NYSE:BMY) announced that they have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime’s proprietary target discovery platform. Five Prime Therapeutics Inc (NASDAQ:FPRX) shares moved up 20.81% in last trading session and was closed at $22.99, while trading in range of $20.63-$23.08. Five Prime Therapeutics Inc (NASDAQ:FPRX) year to date performance is 36.93%.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced that two oral presentations were made at the 23 Asian Pacific Association for the Study of the Liver (APASL) Conference 2014 in Brisbane, Australia. Updated Phase 2 clinical trial results evaluating a 150 mg loading dose followed by 50 mg once daily of ACH-3102 in combination with either once daily 200 mg or 400 mg of sovaprevir and twice daily ribavirin showed that 100% of patients achieved SVR12 (n=8) including subjects who had Y93 mutations at baseline. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) weekly performance is 4.53%. On last trading day company shares ended up $3.46. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) distance from 50-day simple moving average is -1.50%. Analysts mean target price for the company is $4.94.